



Early-life viral infections and the development of asthma: a target for asthma prevention?

Daniel J. Jackson

Purpose of review

To discuss the recent insights into the relationships between viral respiratory infections and asthma inception in the context of a long-term goal of moving toward prevention strategies for childhood asthma.

Recent findings

There is strong evidence for respiratory syncytial virus and human rhinovirus wheezing illnesses as important risk factors for asthma inception. The mechanisms underlying these relationships have been an intense area of study. Novel approaches for the prevention of virus infections and/or lessening the severity of associated illnesses are at various stages of development, and are important potential tools in efforts aimed at primary and secondary prevention of asthma.

Summary

Viral respiratory infections in early life are a major source of morbidity and are critical in the development of asthma. Mechanisms by which these infections lead to asthma inception in susceptible individuals are emerging. Further, there are promising potential interventions currently available that should be tested in clinical trials. The goal of prevention of disease inception is clearly on the horizon.

Keywords

asthma, children, human rhinovirus, prevention, respiratory syncytial virus

INTRODUCTION

The majority of childhood asthma presents with wheezing episodes during the preschool years [1]. Up to 90% of these episodes are triggered by viral respiratory infections during the first 3 years of life [2]. Recently, it has been suggested that infections with pathogenic bacteria may also contribute to wheezing in young children [3]. The relationships between detection of pathogenic bacteria in the airway and asthma inception are discussed by Beigelman *et al.* [4] in this journal. This article will focus on the role of viruses in asthma inception.

WHEEZING PHENOTYPES

In order to define the role of viruses in asthma inception, it is important to discuss when asthma begins. Up to 50% of children will have at least one wheezing illness by school age, and many of these children 'outgrow' their disease. Thus, it has been important to define the wheezing phenotypes in early life to further our understanding of the underlying pathobiology of disease in these children. The Tucson Children's Respiratory Study (TCRS), an unselected birth cohort study [1], has identified

three wheezing phenotypes (persistent, transient early, and late onset). These phenotypes have been further refined in the Avon Longitudinal Study of Parents and Children and Prevention and Incidence of Asthma and Mite Allergy studies to include two additional phenotypes: intermediate onset and prolonged early [5]. Of note, all of these phenotypes are associated with virus-induced wheezing episodes. The most clear distinction among these phenotypes is the degree of underlying atopic features that are present in the children, with intermediate-onset, late-onset, and persistent wheezing children all having the common feature of increased allergic sensitization and other atopic features. Importantly, these three phenotypes are also the most strongly

University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA

Correspondence to Daniel J. Jackson, MD, Assistant Professor of Pediatrics, University of Wisconsin School of Medicine and Public Health, 600 Highland Avenue CSC K4/936, Madison, WI 53792-9988, USA. Tel: +1 608 263 7686; fax: +1 608 265 2207; e-mail: dj@medicine.wisc.edu

Curr Opin Allergy Clin Immunol 2014, 14:131–136

DOI:10.1097/ACI.0000000000000047

KEY POINTS

- Viral respiratory infections are the most common cause of wheezing illnesses during infancy and early life.
- Rhinovirus and RSV infections in early life are critical risk factors for the development of childhood asthma.
- Strategies aimed at preventing rhinovirus and RSV infections or lessening the severity of the associated illnesses are promising approaches for the prevention of asthma.

associated with childhood asthma development. Unfortunately, because these wheezing phenotypes are defined retrospectively at school age, their clinical utility is currently limited.

PULMONARY FUNCTION AND AIRWAY INFLAMMATION IN EARLY LIFE

As a result of the challenges of performing pulmonary function and more invasive studies in young children and the retrospective nature of the wheezing phenotypes described above, our understanding of how wheezing phenotypes relate to airway changes in early life is limited. It has previously been reported that lung function is not significantly lower during infancy but is reduced by school age in children with persistent wheezing [6]. Recently, Bisgaard *et al.* [7[¶]] demonstrated, in a high-risk cohort of infants whose mothers all have asthma, that infants who went on to develop asthma by school age had lower lung function at birth and suffered significant decline during the preschool years. Together, these studies identify the preschool years as a critical window for intervention to prevent loss of lung function over time.

With regard to airway inflammation, Krawiec *et al.* [8] demonstrated that wheezing children with a median age of 14 months have increased numbers of inflammatory cells in bronchoalveolar lavage (BAL) fluid, but do not demonstrate the eosinophil predominance seen in many older children with asthma. Further, Saglani *et al.* [9] performed bronchoscopy and biopsy on recurrent wheezing children and identified that reticular basement membrane (RBM) thickening and eosinophilic inflammation, common features of childhood asthma, were not present at 1 year, but developed by 3 years of age [10] in children with recurrent wheezing. However, it was airway smooth muscle thickness, and not these findings, that correlated with an asthma diagnosis at school age in a follow-up study published recently [11[¶]]. Clearly, new technologies, such as nonionizing MRI [12], are needed for use in young children and

should provide greater understanding of the development of airway changes in early life.

THE ROLE OF VIRUSES IN ASTHMA INCEPTION

Respiratory viral infections can range in severity from asymptomatic to causing an illness severe enough to lead to hospitalization. Improved molecular diagnostics have led to the identification of new species and types of respiratory viruses. Respiratory syncytial virus (RSV), human rhinovirus, influenza, parainfluenza, bocavirus, adenovirus, coronavirus, and human metapneumovirus have all been detected in young children with wheezing illnesses [2,13]. RSV and rhinovirus are the most frequent triggers of wheezing illnesses, thus their role in asthma inception will be the focus of this review.

Respiratory syncytial virus

RSV is the most common cause of severe lower respiratory tract illness leading to hospitalization during infancy, particularly during the first 6 months of life [14]. Early-life RSV wheezing episodes have been associated with the development of recurrent wheezing in numerous studies [15,16]. These relationships are strongest for children with severe RSV illnesses, leading to hospitalization [17]. Mechanisms are emerging from animal models [18] and human studies [19] to identify pathways by which RSV could modify airway and immune development and lead to asthma inception.

The highest level of evidence to date for a causal role of RSV in the development of recurrent wheezing was recently reported by Blanken *et al.* [20[¶]], who performed a clinical trial in preterm infants comparing palivizumab, a monoclonal antibody used for RSV prophylaxis, versus placebo for the prevention of wheezing. They found that palivizumab treatment during RSV season led to a significant reduction in the number of wheezing days and the rate of recurrent wheezing, defined as three or more episodes during the first year of life, from 21 to 11%. These findings are provocative; however, it is unclear whether they will translate to prevention of childhood asthma, as the strength of association between RSV illnesses in infancy, particularly those illnesses not severe enough to lead to hospitalizations, and subsequent recurrent wheezing lessens with age, and was nonsignificant by the age of 13 years in the TCRS [15]. This may relate to the recent observation that maternal atopic asthma is a risk factor for rhinovirus, but not RSV wheezing [21], and atopy is clearly a pivotal risk factor for persistent childhood asthma [22]. Nonetheless, follow-up of

the children enrolled in this trial until school age and beyond will prove very informative.

Rhinovirus

Rhinovirus is the second most common cause of wheezing respiratory illnesses during the first 6 months of life [14], and becomes the most commonly detected pathogen during wheezing illnesses between 6 and 12 months of age [2,23]. Rhinovirus wheezing illnesses have been strongly linked to childhood asthma inception [2,24,25]. In fact, wheezing illnesses caused by rhinovirus during the first 3 years of life have been associated with a 10-fold increase in risk for childhood asthma, compared with a 3-fold risk associated with RSV wheezing [2]. Further, rhinovirus wheezing illnesses in infancy have been linked to lower lung function at school age [26], but whether this represents a cause or effect of rhinovirus wheezing illnesses is not clear.

The study of the relationships between rhinovirus infections and asthma inception is particularly complex, in part because of the fact that there are more than 160 types of rhinoviruses divided into three species: A, B, and C. Rhinovirus infections can cover the spectrum from asymptomatic to severe disease leading to hospitalization. Whether rhinovirus species impacts disease severity has been of enhanced interest recently. Lee *et al.* [27[•]] performed a longitudinal study including samples from infants during periods of wellness and illness, and found that rhinovirus A and C infections were much more likely to lead to moderate-to-severe respiratory illnesses than rhinovirus B infections. Further, several studies [28,29^{••}] have suggested that rhinovirus C infections are more likely to lead to severe illnesses, including those severe enough to lead to hospitalization, when compared with rhinovirus A or B infections. The mechanisms underlying enhanced illness severity with rhinovirus C are currently unclear and are an important area for further study.

An intriguing gene–environment interaction related to rhinovirus infection in early life and asthma inception was recently identified. 17q21 is the most replicated genetic susceptibility locus for childhood asthma [30]. Caliskan *et al.* [31^{••}] found that the 17q21 genotype impacted the risk of subsequent asthma specifically in children who developed wheezing illnesses with rhinovirus infections during early life.

ALLERGIC INFLAMMATION: A CRITICAL RISK FACTOR FOR VIRUS-INDUCED WHEEZING

Early-life allergic sensitization has been identified as an important risk factor for asthma inception [22].

Sensitization to greater numbers of allergens and higher levels of antigen-specific IgE have each been linked to enhanced risk of both wheezing and asthma inception [32,33]. Further, a sequential relationship of allergic sensitization leading to viral, most notably rhinovirus, wheezing in early life has recently been identified [34^{••}]. Once asthma is established, rhinovirus infections in children both sensitized and exposed to aeroallergens are the most likely triggers of asthma exacerbations [35,36]. Highlighting the importance of allergic sensitization to rhinovirus-induced asthma exacerbations in children, treatment with omalizumab (anti-IgE) eliminated fall and spring peaks of asthma exacerbations in inner-city children [37]. This interventional trial provided direct evidence that inhibiting IgE-mediated pathways, including inflammation, leads to a reduction in viral lower respiratory illness severity. On the basis of the recent findings by Cox *et al.* [29^{••}], this may be particularly important for the modification of illness severity for rhinovirus C infections.

The mechanisms by which allergic sensitization and exposure enhance viral illness severity and risk for asthma exacerbations are incompletely understood. Allergic inflammation in the airways leads to impaired barrier function, increased airway responsiveness, and enhanced mucous production [38]. Further, allergic asthma has been associated with deficient innate immune responses to rhinovirus [39–43]. There is also emerging evidence that allergic sensitization and exposure directly impair antiviral responses, as virus-induced type I and III interferon (IFN) production from the plasmacytoid dendritic cells (pDCs) of patients with allergic asthma is impaired by cross-linking of the high-affinity IgE receptor, FcεRI [43,44]. This impaired pDC IFN production may also lead to an enhanced Th2 inflammatory response in the airways [45,46].

TARGETS FOR THE PREVENTION OF ASTHMA?

Taken together, there is substantial evidence for a causal role of viral lower respiratory tract illnesses, both RSV and rhinovirus, in asthma inception during infancy and early childhood. Therefore, preventing RSV and rhinovirus infections and/or lessening the severity of the resulting illnesses are logical and important targets for research across the translational spectrum moving forward. This begs the question, what are the most promising approaches to achieve the goal of prevention of asthma inception?

Respiratory syncytial virus

The only agent currently available for preventing RSV infections is palivizumab. As discussed above, a

recent clinical trial supports the hypothesis that preventing RSV in infancy can decrease the rate of subsequent recurrent wheezing [20²²]. On the basis of the morbidity associated with recurrent wheezing during the preschool years, this is clearly a significant finding. However, it is important, moving forward, to assess whether this translates to a reduction in childhood asthma. There has been great interest in the development of a vaccine for RSV, but this has proven elusive to date. McLellan *et al.* [47²³] used a structure-based approach for the development of an RSV vaccine directed at a specific antigenic site of the virus that is a target of potent RSV-neutralizing antibodies. Their recently reported findings in animal models suggest that this approach yields great promise [47²³]. Ribavirin is the only antiviral currently available for RSV and its use is limited by the side-effects. Other effective small-molecule pharmacologic approaches are clearly needed for RSV, but have been slow to emerge.

Rhinovirus

Unfortunately, there are currently no available therapeutics to prevent rhinovirus infections. In part because of the large diversity of rhinoviruses, development of a vaccine has remained challenging, although efforts to produce an effective vaccine are ongoing [48] and a potentially promising strategy for asthma prevention. Many small-molecule approaches to ‘curing the common cold’ have been tested over the years and have, for the most part, been quite disappointing. One example is pleconaril, a capsid-binding agent, that led to modestly decreased cold symptom scores and shortened duration of the illness, but side-effects and medication interactions hampered its further development [49]. As noted above, rhinovirus C species may be associated with the greatest burden of lower respiratory illness, and recent studies suggest that the structure of rhinovirus C may have led the previously tested antivirals to be ineffective for this particular species, which may have negatively impacted some of the studies of small molecules to date [50²⁴]. Future studies aimed at developing therapeutics toward rhinovirus C are clearly a priority.

A variety of strategies have the potential to lessen the severity of rhinovirus infections by targeting the host-susceptibility factors for more severe disease. On the basis of the strong associations among allergic sensitization, virus-induced wheezing, and asthma inception and exacerbation, it is very logical to propose that interventions aimed at the prevention of allergic sensitization and allergic inflammation have the potential to prevent asthma development.

Omalizumab, a monoclonal antibody directed at IgE, is approved for use in patients with allergic asthma who are of age 12 years and above. It has shown significant benefit in the prevention of asthma exacerbations down to 6 years of age, with the greatest benefits seen in patients who are sensitized and exposed to aeroallergens [37]. Therefore, the use of omalizumab to block IgE-mediated inflammation in preschool children at high risk of asthma development is a promising approach for asthma prevention.

Additionally, other monoclonal antibodies aimed at Th2 inflammatory pathways have shown promise in the prevention of exacerbations in adult patients with refractory disease [51–53]. However, these agents are not yet approved in the United States for asthma treatment, so it would likely be premature to study their effectiveness for the prevention of disease in preschool children. Further, inhaled interferon- β is currently in human trials in adults as a potential treatment to augment the host response to rhinovirus and prevent asthma exacerbations. If effective, this approach would also warrant testing in children moving forward.

Finally, there is great interest on the role of early microbial exposures in the development of allergic sensitization, viral wheezing, and asthma [54]. Data ranging from early-life farm exposures [55] to pet exposures [56,57] suggest that particular microbial exposures during infancy can decrease risk for the development of allergic diseases, including asthma. OM-85BV, a mixture of lyophilized bacteria, has recently been reported to reduce the rate of wheezing episodes in a pilot study [58] in preschool children. Animal studies [59] suggest potential mechanisms by which this product could prevent disease. In sum, the hypothesis that early-life microbial exposures could be a cost-effective means of primary asthma prevention is intriguing. However, studies of the microbiome in health and disease are currently in their infancy, and to maximize our chances for success with these interventions, these studies should remain a priority moving forward.

CONCLUSION

Wheezing viral respiratory infections, most notably with rhinovirus and RSV, are the most common initial presentation of asthma in early life. There are substantial data in support of a causal role for these viruses in asthma inception. Once asthma is established, rhinovirus is the primary trigger of asthma exacerbations. We are at an exciting time in asthma research. Continued efforts to identify the mechanisms by which viruses interact with susceptible hosts to induce asthma are clearly needed.

However, there are promising potential interventions currently available that should be tested in clinical trials. The goal of prevention of disease inception is clearly on the horizon.

Acknowledgements

None.

Conflicts of interest

The author has no relevant conflicts of interest.

NIH funding: D.J.J. was supported by the Clinical and Translational Science Award (CTSA) program through the NIH National Center for Advancing Translational Sciences (NCATS), grant UL1TR000427. The content is solely the responsibility of the author and does not necessarily represent the official views of the NIH.

REFERENCES AND RECOMMENDED READING

Papers of particular interest, published within the annual period of review, have been highlighted as:

- of special interest
- of outstanding interest

1. Martinez FD, Wright AL, Taussig LM, *et al.* Asthma and wheezing in the first six years of life. *N Engl J Med* 1995; 332:133–138.
2. Jackson DJ, Gangnon RE, Evans MD, *et al.* Wheezing rhinovirus illnesses in early life predict asthma development in high-risk children. *Am J Respir Crit Care Med* 2008; 178:667–672.
3. Bisgaard H, Hermansen MN, Bonnellykke K, *et al.* Association of bacteria and viruses with wheeze episodes in young children: prospective birth cohort study. *BMJ* 2010; 341:c4978.
4. Beigelman A, Weinstock GM, Bacharier LB. The relationships between environmental bacterial exposure, airway bacterial colonization, and asthma. *Curr Opin Allergy Clin Immunol* 2014; 14:137–142.
5. Savenije OE, Granell R, Caudri D, *et al.* Comparison of childhood wheezing phenotypes in 2 birth cohorts: ALSPAC and PIAMA. *J Allergy Clin Immunol* 2011; 127:1505.e14–1512.e14.
6. Morgan WJ, Stern DA, Sherrill DL, *et al.* Outcome of asthma and wheezing in the first 6 years of life: follow-up through adolescence. *Am J Respir Crit Care Med* 2005; 172:1253–1258.
7. Bisgaard H, Jensen SM, Bonnellykke K. Interaction between asthma and lung function growth in early life. *Am J Respir Crit Care Med* 2012; 185:1183–1189.
8. Krawiec ME, Westcott JY, Chu HW, *et al.* Persistent wheezing in very young children is associated with lower respiratory inflammation. *Am J Respir Crit Care Med* 2001; 163:1338–1343.
9. Saglani S, Malmstrom K, Pelkonen AS, *et al.* Airway remodeling and inflammation in symptomatic infants with reversible airflow obstruction. *Am J Respir Crit Care Med* 2005; 171:722–727.
10. Saglani S, Payne DN, Zhu J, *et al.* Early detection of airway wall remodeling and eosinophilic inflammation in preschool wheezers. *Am J Respir Crit Care Med* 2007; 176:858–864.
11. O'Reilly R, Ullmann N, Irving S, *et al.* Increased airway smooth muscle in preschool wheezers who have asthma at school age. *J Allergy Clin Immunol* 2013; 131:1024.e16–1032.e16.
12. Cadman RV, Lemanske RF Jr, Evans MD, *et al.* Pulmonary ³He magnetic resonance imaging of childhood asthma. *J Allergy Clin Immunol* 2013; 131:369–376.
13. Edwards KM, Zhu Y, Griffin MR, *et al.* Burden of human metapneumovirus infection in young children. *N Engl J Med* 2013; 368:633–643.
14. Mansbach JM, Piedra PA, Teach SJ, *et al.* Prospective multicenter study of viral etiology and hospital length of stay in children with severe bronchiolitis. *Arch Pediatr Adolesc Med* 2012; 166:700–706.
15. Stein RT, Sherrill D, Morgan WJ, *et al.* Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. *Lancet* 1999; 354:541–545.
16. Sigurs N, Gustafsson PM, Bjarnason R, *et al.* Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. *Am J Respir Crit Care Med* 2005; 171:137–141.
17. Carroll KN, Wu P, Gebretsadik T, *et al.* The severity-dependent relationship of infant bronchiolitis on the risk and morbidity of early childhood asthma. *J Allergy Clin Immunol* 2009; 123:1055–1061.
18. Krishnamoorthy N, Khare A, Oriss TB, *et al.* Early infection with respiratory syncytial virus impairs regulatory T cell function and increases susceptibility to allergic asthma. *Nat Med* 2012; 18:1525–1530.
19. Mejias A, Dimo B, Suarez NM, *et al.* Whole blood gene expression profiles to assess pathogenesis and disease severity in infants with respiratory syncytial virus infection. *PLoS Med* 2013; 10:e1001549.
20. Blanken MO, Rovers MM, Molenaar JM, *et al.* Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. *N Engl J Med* 2013; 368:1791–1799.
21. Carroll KN, Gebretsadik T, Minton P, *et al.* Influence of maternal asthma on the cause and severity of infant acute respiratory tract infections. *J Allergy Clin Immunol* 2012; 129:1236–1242.
22. Sly PD, Boner AL, Bjorksten B, *et al.* Early identification of atopy in the prediction of persistent asthma in children. *Lancet* 2008; 372:1100–1106.
23. Korppi M, Kotaniemi-Syrjanen A, Waris M, *et al.* Rhinovirus-associated wheezing in infancy: comparison with respiratory syncytial virus bronchiolitis. *Pediatr Infect Dis J* 2004; 23:995–999.
24. Kotaniemi-Syrjanen A, Vainionpaa R, Reijonen TM, *et al.* Rhinovirus-induced wheezing in infancy – the first sign of childhood asthma? *J Allergy Clin Immunol* 2003; 111:66–71.
25. Kusel MM, de Klerk NH, Kebabdz T, *et al.* Early-life respiratory viral infections, atopic sensitization, and risk of subsequent development of persistent asthma. *J Allergy Clin Immunol* 2007; 119:1105–1110.
26. Guilbert TW, Singh AM, Danov Z, *et al.* Decreased lung function after preschool wheezing rhinovirus illnesses in children at risk to develop asthma. *J Allergy Clin Immunol* 2011; 128:532–580.
27. Lee WM, Lemanske RF Jr, Evans MD, *et al.* Human rhinovirus species and season of infection determine illness severity. *Am J Respir Crit Care Med* 2012; 186:886–891.
28. Linder JE, Kraft DC, Mohamed Y, *et al.* Human rhinovirus C: age, season, and lower respiratory illness over the past 3 decades. *J Allergy Clin Immunol* 2013; 131:69–77.
29. Cox DW, Bizzintino J, Ferrari G, *et al.* Human rhinovirus species C infection in young children with acute wheeze is associated with increased acute respiratory hospital admissions. *Am J Respir Crit Care Med* 2013; 188:1358–1364.
30. Torgerson DG, Ampleford EJ, Chiu GY, *et al.* Meta-analysis of genome-wide association studies of asthma in ethnically diverse North American populations. *Nat Genet* 2011; 43:887–892.
31. Caliskan M, Bochkov YA, Kreiner-Moller E, *et al.* Rhinovirus wheezing illness and genetic risk of childhood-onset asthma. *N Engl J Med* 2013; 368:1398–1407.
32. Simpson A, Tan VY, Winn J, *et al.* Beyond atopy: multiple patterns of sensitization in relation to asthma in a birth cohort study. *Am J Respir Crit Care Med* 2010; 181:1200–1206.
33. Stoltz DJ, Jackson DJ, Evans MD, *et al.* Specific patterns of allergic sensitization in early childhood and asthma & rhinitis risk. *Clin Exp Allergy* 2013; 43:233–241.
34. Jackson DJ, Evans MD, Gangnon RE, *et al.* Evidence for a causal relationship between allergic sensitization and rhinovirus wheezing in early life. *Am J Respir Crit Care Med* 2012; 185:281–285.
35. Heymann PW, Carper HT, Murphy DD, *et al.* Viral infections in relation to age, atopy, and season of admission among children hospitalized for wheezing. *J Allergy Clin Immunol* 2004; 114:239–247.
36. Soto-Quiros M, Avila L, Platts-Mills TA, *et al.* High titers of IgE antibody to dust mite allergen and risk for wheezing among asthmatic children infected with rhinovirus. *J Allergy Clin Immunol* 2012; 129:1499.e5–1505.e5.
37. Busse WW, Morgan WJ, Gergen PJ, *et al.* Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. *N Engl J Med* 2011; 364:1005–1015.
38. Kloepper KM, Gern JE. Virus/allergen interactions and exacerbations of asthma. *Immunol Allergy Clin North Am* 2010; 30:553–563.

This clinical trial provides direct evidence for RSV infection in the development of recurrent wheezing during infancy. Long-term follow-up of this cohort will prove informative.

This study in infants identified both rhinovirus A and rhinovirus C as important causes of moderate-to-severe respiratory illnesses using assessments during both times of illness and when children were well.

This study identified a gene by pathogen interaction, linking 17q21 genotype effects on asthma risk to children who wheeze with rhinovirus infections.

Through modeling of a high-risk birth cohort, this study identified a sequential relationship with allergic sensitization leading to rhinovirus wheezing in early life.

39. Sykes A, Edwards MR, Macintyre J, *et al.* Rhinovirus 16-induced IFN- α and IFN- β are deficient in bronchoalveolar lavage cells in asthmatic patients. *J Allergy Clin Immunol* 2012; 129:1506.e6–1514.e6.
40. Baraldo S, Contoli M, Bazzan E, *et al.* Deficient antiviral immune responses in childhood: distinct roles of atopy and asthma. *J Allergy Clin Immunol* 2012; 130:1307–1314.
41. Wark PA, Johnstone SL, Bucchieri F, *et al.* Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. *J Exp Med* 2005; 201:937–947.
42. Contoli M, Message SD, Laza-Stanca V, *et al.* Role of deficient type III interferon-lambda production in asthma exacerbations. *Nat Med* 2006; 12:1023–1026.
43. Durrani SR, Montville DJ, Pratt AS, *et al.* Innate immune responses to rhinovirus are reduced by the high-affinity IgE receptor in allergic asthmatic children. *J Allergy Clin Immunol* 2012; 130:489–495.
44. Gill MA, Bajwa G, George TA, *et al.* Counterregulation between the Fc ϵ RI pathway and antiviral responses in human plasmacytoid dendritic cells. *J Immunol* 2010; 184:5999–6006.
45. Pritchard AL, Carroll ML, Burel JG, *et al.* Innate IFNs and plasmacytoid dendritic cells constrain Th2 cytokine responses to rhinovirus: a regulatory mechanism with relevance to asthma. *J Immunol* 2012; 188:5898–5905.
46. Huber JP, Ramos HJ, Gill MA, Farrar JD. Cutting edge: type I IFN reverses human Th2 commitment and stability by suppressing GATA3. *J Immunol* 2010; 185:813–817.
47. McLellan JS, Chen M, Joyce MG, *et al.* Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. *Science* 2013; 342:592–598.
- A novel approach to RSV vaccine development shows significant promise in this study.
48. McLean GR, Walton RP, Shetty S, *et al.* Rhinovirus infections and immunisation induce cross-serotype reactive antibodies to VP1. *Antivir Res* 2012; 95:193–201.
49. Hayden FG, Herrington DT, Coats TL, *et al.* Efficacy and safety of oral pleconaril for treatment of colds due to picornaviruses in adults: results of 2 double-blind, randomized, placebo-controlled trials. *Clin Infect Dis* 2003; 36:1523–1532.
50. Basta HA, Ashraf S, Sgro JY, *et al.* Modeling of the human rhinovirus C capsid ■ suggests possible causes for antiviral drug resistance. *Virology* 2014; 448:82–90.
- This study identifies potential structural mechanisms for enhanced virulence of rhinovirus C.
51. Wenzel S, Ford L, Pearlman D, *et al.* Dupilumab in persistent asthma with elevated eosinophil levels. *N Engl J Med* 2013; 368:2455–2466.
52. Corren J, Lemanske RF, Hanania NA, *et al.* Lebrikizumab treatment in adults with asthma. *N Engl J Med* 2011; 365:1088–1098.
53. Pavord ID, Korn S, Howarth P, *et al.* Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. *Lancet* 2012; 380:651–659.
54. Han MK, Huang YJ, Lipuma JJ, *et al.* Significance of the microbiome in obstructive lung disease. *Thorax* 2012; 67:456–463.
55. Ege MJ, Mayer M, Normand AC, *et al.* Exposure to environmental micro-organisms and childhood asthma. *N Engl J Med* 2011; 364:701–709.
56. Fujimura KE, Johnson CC, Ownby DR, *et al.* Man's best friend? The effect of pet ownership on house dust microbial communities. *J Allergy Clin Immunol* 2010; 126:410–422.
57. Ownby DR, Johnson CC, Peterson EL. Exposure to dogs and cats in the first year of life and risk of allergic sensitization at 6 to 7 years of age. *JAMA* 2002; 288:963–972.
58. Razi CH, Harmanici K, Abaci A, *et al.* The immunostimulant OM-85 BV prevents wheezing attacks in preschool children. *J Allergy Clin Immunol* 2010; 126:763–769.
59. Strickland DH, Judd S, Thomas JA, *et al.* Boosting airway T-regulatory cells by gastrointestinal stimulation as a strategy for asthma control. *Mucosal Immunol* 2011; 4:43–52.